Rathbones Group PLC Has $318,000 Stock Position in Gilead Sciences, Inc. $GILD

Rathbones Group PLC lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,870 shares of the biopharmaceutical company’s stock after selling 473 shares during the quarter. Rathbones Group PLC’s holdings in Gilead Sciences were worth $318,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. GoalVest Advisory LLC lifted its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Activest Wealth Management lifted its position in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the 2nd quarter valued at $27,000. Putney Financial Group LLC boosted its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares in the last quarter. Finally, Colonial Trust Advisors raised its stake in Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on GILD shares. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $143.00 to $153.00 in a research note on Monday. Argus raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Morgan Stanley increased their price target on Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Finally, Royal Bank Of Canada raised their target price on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $128.27.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of GILD stock opened at $122.56 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The firm has a market cap of $152.07 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 0.81 and a beta of 0.32. The stock has a 50-day moving average price of $116.79 and a 200 day moving average price of $112.48.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the company earned $2.02 EPS. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.